Indian Courts Draw Ethical and Procedural Lines in Patent and Insolvency Law

New Delhi – In two significant but distinct rulings, Indian appellate courts have delivered crucial judgments on the intersection of law, ethics, and procedural fairness, reinforcing judicial oversight in intellectual property and corporate insolvency. The Calcutta High Court has affirmed a landmark decision barring the patentability of inventions requiring the destruction of human embryos, while the National Company Law Appellate Tribunal (NCLAT) has strongly rebuked a lower tribunal for erroneously disqualifying the promoters of an MSME from the insolvency resolution process.

These decisions, while rooted in different statutes, share a common thread: the judiciary's role in interpreting and applying legal provisions that touch upon public morality and the equitable application of the law. They provide critical guidance for legal practitioners in the burgeoning fields of biotechnology patent law and the dynamic landscape of the Insolvency and Bankruptcy Code (IBC).

---

Calcutta High Court Upholds "Public Morality" Bar on Embryo-Destroying Inventions

In a judgment with profound implications for biotechnology and patent law in India, the Calcutta High Court has upheld the Indian Patent Office's refusal to grant a patent for an invention involving human embryonic stem cells, citing that its commercial exploitation would be contrary to public order and morality.

The single-judge bench of Justice Ravi Krishan Kapur, in the case of Shroff Geeta v. Asst. Controller Of Patents And Design , affirmed that inventions necessitating the destruction of human embryos fall squarely within the prohibitions of Section 3(b) of the Patents Act, 1970.

This provision excludes from patentability "an invention the primary or intended use or commercial exploitation of which could be contrary to public order or morality or which causes serious prejudice to human, animal or plant life or health or to the environment."

Background of the Dispute

The case originated from a patent application filed in September 2008 by Shroff Geeta for an invention that contained human embryonic stem cells and their derivatives. After a decade of examination, the Patent Office rejected the application in September 2018. The Controller reasoned that the invention's methodology, which required the collection of 2-to-7-day-old human embryos to derive stem cell lines, inherently involved the destruction of those embryos. This act, the Controller concluded, was unethical and violated the "public order or morality" clause of Section 3(b).

The applicant appealed to the High Court, arguing that the Patent Office had misinterpreted the scope of Section 3(b) and contended that the invention did not necessarily involve destroying human embryos.

The High Court's Rationale

Justice Kapur’s bench meticulously dismantled the appellant's arguments, siding with the Patent Office's interpretation. The court underscored that the core of the invention relied on the "destructive use of human embryos at a delicate stage of development."

The judgment states, “The invention requires the use of human embryos for industrial or commercial purposes within the meaning of section 3(b) of Act. Such use of human embryonic stem cells obtained through extraction from the embryo leading to abortion or destruction of embryo has been held to be unethical.”

The court's analysis focused on several key aspects:

1. Statutory Interpretation: It affirmed that Section 3(b) mandates an evaluation of the invention's primary use, its potential for harmful commercial exploitation, and its alignment with public morality. The court found no error in the Controller's application of this test.
   
   
2. Ethical Considerations: The court explicitly agreed that deriving embryonic stem cell lines through extraction is tantamount to the destruction of a human embryo. This position was fortified by referencing the National Guidelines for Stem Cell Research, 2017, aligning the legal interpretation with the national scientific and ethical consensus.
3. International Precedent: The court drew upon international jurisprudence, including Article 53(a) of the Paris Convention and the Canadian Supreme Court case of Harvard College v. Canada (Commissioner of Patents) , to highlight the global principle that patent law is not a value-neutral domain and rightly avoids granting state-sanctioned monopolies to inventions that raise grave ethical questions.

By dismissing the appeal, the Calcutta High Court has drawn a clear ethical boundary for patent law in India. The ruling sends an unequivocal message to innovators and corporations in the biotechnology sector that scientific advancement cannot be divorced from fundamental moral considerations, particularly when it involves the potential for human life. For IP lawyers, this judgment serves as a critical precedent in advising clients on the patentability of inventions in sensitive areas like genetic engineering and stem cell research.

---

NCLAT Reverses "Perverse" Promoter Disqualification in MSME Insolvency

In the corporate insolvency sphere, the National Company Law Appellate Tribunal (NCLAT) delivered a scathing rebuke to the National Company Law Tribunal (NCLT), New Delhi, for what it termed a "callous" and "perverse" decision to disqualify the promoters of an MSME from submitting a resolution plan for their own company.

The NCLAT bench, comprising Chairperson Justice Ashok Bhushan and Member Barun Mitra, overturned the NCLT's July 2023 order in Dr Vijay Kant Dixit & Anr vs Amrapali Fincap Ltd. & Ors. , restoring the promoters' resolution plan for consideration and directing the NCLT to decide on its approval within three months.

The Flawed Disqualification

The case involved JC World Hospitality Pvt Ltd, an MSME real estate company that entered insolvency in 2019. The company's promoters, Vijay Kant Dixit and Vasudha Gaur Dixit, submitted a resolution plan that won the approval of the Committee of Creditors (CoC), which was composed entirely of homebuyers.

However, a competing bidder, Amrapali Fincap Ltd., challenged the promoters' eligibility under Section 29A of the IBC. The NCLT sided with Amrapali, disqualifying the promoters on several grounds, including alleged NPA status, director disqualification under the Companies Act, and insufficient net worth.

NCLAT's Point-by-Point Reversal

The NCLAT systematically dismantled each of the NCLT's findings, branding them as "wholly erroneous," "unsustainable," and based on a "clearly erroneous" appreciation of evidence.

1. On Director Disqualification: The NCLT had found the promoters disqualified under Section 164(2) of the Companies Act. The NCLAT, however, pointed to clear evidence on record, including a 2023 email from the Ministry of Corporate Affairs (MCA) and prior High Court orders, confirming their Director Identification Numbers (DINs) were active and compliant. The appellate tribunal stated, “We, thus, are of the view that the Adjudicating Authority in a callous manner without looking into materials on record have come to conclusion that [the promoters] are disqualified... which reason and finding is perverse and unsustainable.”
2. On NPA Status: The NCLAT found the NCLT's conclusion that the promoters' accounts were declared Non-Performing Assets (NPAs) to be "unfounded and cannot be sustained," indicating a lack of supporting evidence for such a critical finding.
3. MSME Protections: The NCLAT implicitly reinforced the legislative intent behind Section 240A of the IBC, which exempts promoters of MSMEs from certain ineligibility criteria under Section 29A. While the specific grounds of disqualification were debunked on their merits, the context of the debtor being an MSME was a crucial backdrop.

The NCLAT's decision is a significant victory for MSME promoters facing insolvency. It underscores that disqualification under Section 29A is a serious matter that requires rigorous proof and cannot be based on unsubstantiated allegations or a superficial examination of facts. The ruling serves as a powerful reminder to Adjudicating Authorities to conduct thorough due diligence and avoid "callous" findings that can unjustly derail a CoC-approved resolution plan.

For insolvency professionals, this judgment clarifies the evidentiary standards for Section 29A challenges and reinforces the appellate tribunal's willingness to intervene decisively when lower tribunals commit manifest errors of fact and law. It highlights the importance of a meticulously prepared record to defend against or support eligibility challenges.